Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden

Single-agent immune checkpoint blockade has shown no clinical benefits in pancreatic cancer. Recently, the programmed cell death protein 1 (PD-1) antibody pembrolizumab has been recommended as a treatment option for high tumor mutational burden (TMB) solid tumors based on the data from a basket tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Mengyao, Sheng, Jianpeng, Zhang, Qi, Wang, Jianxin, Fu, Qihan, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016350/
https://www.ncbi.nlm.nih.gov/pubmed/36937383
http://dx.doi.org/10.3389/fonc.2023.1118633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016350/
https://www.ncbi.nlm.nih.gov/pubmed/36937383
http://dx.doi.org/10.3389/fonc.2023.1118633

Ejemplares similares